Novartis Biosimilar Pipeline, 2018 Growth Plans On Track
Zacks Investment Research | May 31, 2017 05:30AM ET
Novartis AG (NYSE:NVS) announced that the European Medicines Agency (EMA) has accepted the company’s Marketing Authorization Applications for biosimilar versions of AbbVie's (NYSE:ABBV) Humira (adalimumab) and Johnson & Johnson’s (NYSE:JNJ) Remicade (infliximab) for review.
Sandoz is seeking approval for use in all indications for which the drugs are approved. Sandoz currently markets three biosimilars – Omnitrope, a human growth hormone; Binocrit, an erythropoiesis-stimulating agent; and Zarxio – in the U.S. In addition, Sandoz has a strong pipeline of biosimilars including Roche’s (OTC:RHHBY) Rituxan.
In Apr 2017, the CHMP gave positive opinion on biosimilar versions of Rituxan and Enbrel. Hence, Novartis is on track to launch five biosimilars of major oncology and immunology biologics by 2020.
Concurrently, Novartis shed light on its long-term plans as well. The company expects the next growth phase to begin in 2018 driven by Cosentyx (in all three indications psoriasis, psoriatic arthritis and ankylosing spondylitis (AS)) Entresto, and Kisqali and a deep pipeline with candidates like CTL019, BAF312, AMG 334, RTH258. We note that Cosentyx attained the blockbuster status in 2016.
The company is, however, facing significant pricing pressures in the U.S. in its Sandoz division and the impact of the delayed launch of Glatopa 40mg are likely to impact the second-quarter results.
Meanwhile, Novartis is conducting a strategic review of the Alcon Division and exploring all options to maximize value for shareholders. The company stated that the review is on track and will provide a status update for the same toward the end of 2017.
So far in the year, Novartis has outperformed the Zacks classified industry. The stock has rallied 12.3% compared with the Large Cap Pharmaceuticals industry’s gain of 9%.
Zacks Rank
Novartis currently carries a Zacks Rank #3 (Hold). You can see .
More Stock News: 8 Companies Verge on Apple-Like Run
Did you miss Apple (NASDAQ:AAPL)'s 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.
Get The News You Want
A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.